Inventiva Phase 2 Study: Lanifibranor Success in MASH Patients
Monday, 18 March 2024, 21:45
Inventiva Phase 2 Study on Lanifibranor
In a significant development, Inventiva's Phase 2 study on lanifibranor has achieved success by meeting its primary efficacy endpoint in treating patients with MASH/NASH and type 2 diabetes.
Promising Results for Healthcare
The positive outcome of the study highlights the potential breakthrough in addressing critical health conditions, offering hope for patients suffering from these diseases.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.